About Applied BioCode
Applied BioCode is a company based in Santa Fe Springs (United States) founded in 2008. Applied BioCode has raised $20.29 million across 6 funding rounds from investors including NIH and HHS. Applied BioCode offers products and services including BioCode® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCode® SARS-CoV-2 Assay, and BioCode® STI + Resistance Panel. Applied BioCode operates in a competitive market with competitors including Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
- Headquarter Santa Fe Springs, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Applied Biocode Corp.
-
Annual Revenue
$343.07 M-13.18as on Dec 31, 2024
-
Net Profit
-$260.81 M-58.84as on Dec 31, 2024
-
EBITDA
-$216.51 M-74.58as on Dec 31, 2024
-
Total Equity Funding
$20.29 M (USD)
in 6 rounds
-
Latest Funding Round
$9.26 M (USD), Series A
Apr 07, 2016
-
Investors
NIH
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Applied BioCode
Applied BioCode is a publicly listed company on the TWSE with ticker symbol 6598 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Applied BioCode
Applied BioCode offers a comprehensive portfolio of products and services, including BioCode® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCode® SARS-CoV-2 Assay, and BioCode® STI + Resistance Panel.
High-throughput system for multiplex pathogen testing
Detects pathogens for gastroenteritis in clinical settings
Identifies common respiratory infection causes
Enables pooled testing for COVID-19 detection
Detects sexually transmitted infections and resistance
People of Applied BioCode
Unlock access to complete
Funding Insights of Applied BioCode
Applied BioCode has successfully raised a total of $20.29M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $9.26 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $9.3M
-
First Round
First Round
(07 Jul 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2016 | Amount | Series A - Applied BioCode | Valuation |
investors |
|
| Dec, 2012 | Amount | Series A - Applied BioCode | Valuation |
investors |
|
| Sep, 2012 | Amount | Grant - Applied BioCode | Valuation |
investors |
Investments & Acquisitions by Applied BioCode
Financial Statements - Applied BioCode
Applied Biocode Comparisons
Competitors of Applied BioCode
Applied BioCode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| domain | founded_year | HQ Location |
Primary antibodies and instruments for immunohistochemistry are manufactured.
|
|
| domain | founded_year | HQ Location |
Merck is engaged in science and technology solutions globally.
|
|
| domain | founded_year | HQ Location |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| domain | founded_year | HQ Location |
Online platform offering life sciences reagents and kits
|
|
| domain | founded_year | HQ Location |
Portfolio of products and services for life science research and clinical diagnostic markets
|
Frequently Asked Questions about Applied BioCode
Applied BioCode was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Applied BioCode is headquartered in Santa Fe Springs, United States. It is registered at Santa Fe Springs, California, United States.
Applied BioCode is a funded company, having raised a total of $20.29M across 6 funding rounds to date. The company's 1st funding round was a Grant of $120.92K, raised on Jul 07, 2010.
Developer of assay testing kits and instruments for in vitro diagnostics, research, and other industrial applications. The company develops, manufactures, and commercializes multiplex diagnostic testing products that inlcudes testing assays that detect pathogens for gastrointestinal infections, respiratory infections, and other high-value diseases. Also, it offers a BioCode MDx-3000 system with a 17-plex Gastrointestinal Pathogen Panel (GPP) and a 17-plex Respiratory Pathogen Panel (RPP).
Applied BioCode's top competitors include Biocare Medical, Merck and Siemens Healthineers.
Applied BioCode offers BioCode® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCode® SARS-CoV-2 Assay, and BioCode® STI + Resistance Panel.
Yes, Applied BioCode is publicly traded on TWSE under the ticker symbol 6598.
The ticker symbol of Applied BioCode is 6598 on TWSE.